سعر نافونوزيا 0.25مجم/5مل فيال 2022

Navonausia 0.25 mg/5 ml IV vial (Global Pharmaceutical Industries, Egypt): palonosetron for IV injection or infusion.

• Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately or highly emetogenic cancer chemotherapy; prevention of postoperative nausea and vomiting (PONV) for up to 24 hours after surgery.Population: AdultsDailyMed / FDA

• Common adverse reactions with IV palonosetron include headache, constipation, and bradycardia (US label).International label, same formulation · DailyMed / FDA

• Known hypersensitivity to palonosetron or any component of the formulation.International label, same formulation · DailyMed / FDA

• Hypersensitivity reactions, including anaphylaxis, have been reported with palonosetron.International label, same formulation · DailyMed / FDA
• Serotonin syndrome can occur with 5-HT3 antagonists, particularly with concomitant serotonergic drugs (SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue).International label, same formulation · DailyMed / FDA

• SSRIs/SNRIs and other serotonergic drugsMajorIncreased risk of serotonin syndrome when combined with 5-HT3 antagonists.DailyMed / FDA

• Available data with palonosetron use in pregnant women are insufficient to inform a drug-associated risk; animal studies did not show teratogenicity at exposures similar to clinical doses (US label).International label, same formulation · DailyMed / FDA
• Unknown whether palonosetron is present in human milk; consider developmental and health benefits of breastfeeding along with clinical need (US label).International label, same formulation · DailyMed / FDA

• Palonosetron: Blocks serotonin 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone.